BrainStorm Cell Therapeutics Inc. Receives United States Patent Office Notice Of Allowance For Its Stem Cell Technology

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has received a Notice of Allowance from the U.S. Patent Office for its "Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases" (serial number 11/727,583) patent application.

Help employers find you! Check out all the jobs and post your resume.

Back to news